U PDAT E

M-LINE I 800-962-3555 I mcancer.org

j A N U A r y 2 0 1 3

New clinical trial tests targeting prostate cancer treatment to gene fusion

Laboratory research, which originated at U-M, has suggested that the enzyme PArP is required for the gene fusion to contribute to the cancer growth and progression. By blocking PArP in the lab, researchers were able to impact the cancer growth, particularly in combination with hormone therapy. This new clinical trial tests that finding in patients.

Trial participants will be stratified based on their gene fusion status. All participants will receive the standard hormone-based therapy abiraterone. Each group – gene fusion positive and gene fusion negative – will then be randomized so half of participants will also take an experimental PArP-1 targeted therapy called ABT-888 in addition to abiraterone.

A new phase 2 clinical trial will test whether targeting treatments to a genetic anomaly can lead to more targeted treatment for prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 12 sites throughout the country. The trial will look at patients with castration-resistant metastatic prostate cancer. Patients must undergo a biopsy of a metastatic site as the first step in participating, so that researchers can test the tumor for the TMPrSS2:ErG gene fusion, a genetic anomaly in which two genes fuse together to create a hybrid gene. This fusion, which occurs in more than half of all prostate cancers, is believed to cause the cancer. “We hope this study will help us understand why certain patients respond to therapy and certain patients do not. By better understanding the evolving biology of prostate cancer, we will have the ability to better treat the disease,” says the study’s principal investigator, Maha Hussain, M.D., professor of internal medicine and urology, and associate director of clinical research at the U-M Comprehensive Cancer Center.

“Do patients who have the gene fusion respond even better when ABT-888 is added? We hope that what we learn from this study will help us to better control and better treat the deadly stage of prostate cancer,” Hussain says.

“In order to beat your enemy you’ve got to understand it. We are getting closer and closer to understanding the enemy which is cancer,” she adds.

For information about referring your

patients to this trial, “A Randomized Gene

Fusion-Stratified Phase 2 Trial of Abiraterone

with or without ABT-888 for Patients with

Metastatic Castration-Resistant Prostate

Cancer,” call MLINE at 800-962-3555.

Study principal investigator, Maha Hussain, M.D., professor of internal medicine and urology, and associate director of clinical research at the U-M Comprehensive Cancer Center.

New facult y

M-LINE I 800-962-3555 I mcancer.org

Jessica Bensenhaver, M.D.Multidisciplinary Breast Care Clinic

Clinical Lecturer, Surgery. She completed her residency at Charleston Area Medical Center (Charleston, WV) and is a graduate of joan C. Edwards School of Medicine at Marshall University (Huntington, WV).

Monika Burness, M.D.Multidisciplinary Breast Cancer Clinic

Clinical Lecturer, Hematology/Oncology. She completed her fellowship at the University of Chicago Medical Center (Chicago, IL) and her residency at the johns Hopkins School of Medicine (Baltimore, MD). Dr. Burness is a graduate of Penn State College of Medicine (Hershey, PA).

Rami Khoriaty, M.D.Hematology Clinic

Clinical Lecturer, Hematology/Oncology. He completed his fellowship at the University of Michigan (Ann Arbor, MI), and his residency at Cleveland Clinic Hospital (Cleveland, OH). Dr. Khority is a graduate of the American University of Beirut (Lebanon).

Todd Morgan, M.D.Multidisciplinary Urologic Oncology Clinic

Assistant Professor, Urology. He completed his fellowship at Vanderbilt University Medical Center (Nashville, TN) and his residency at the University of Washington Medical Center (Seattle, WA). He is a graduate of Harvard Medical School (Boston, MA).

The U-M Comprehensive Cancer Center has added new faculty to enhance the multi-disciplinary care offered throughout the center.

M-LINE I 800-962-3555 I mcancer.org

Ganesh Palapattu, M.D., FACSMultidisciplinary Urologic Oncology Clinic

Chief, Urologic Oncology and Associate Professor, Urology. He completed his fellowship at the johns Hopkins School of Medicine (Baltimore, MD) and his residency at UCLA Medical Center (Los Angeles, CA). He is a graduate of Baylor College of Medicine (Houston, TX).

Tycel Phillips, M.D.Hematology Clinic

Clinical Lecturer, Hematology/Oncology. He completed his fellowship at Case Medical Center (Cleveland, OH ) and his residency at john H. Stroger Hospital of Cook County (Chicago, IL). Dr. Phillips is a graduate of rush Medical College (Chicago, IL).

Rupali Roy, M.D.Hematology Clinic

Clinical Lecturer, Hematology/Oncology. She completed her fellowship at Northwestern University McGaw Medical Center (Chicago, IL) and her residency at the University of Virginia Hospitals (Charlottesville, VA). Dr. roy is a graduate of the University of Arizona College of Medicine (Tucson, AZ).

If you would like an introduction to these or any of the U-M Comprehensive Cancer Center’s faculty, please let Physician Liaison Laurie Powell know at beckwith@med.umich.edu or call M-Line at 800-962-3555.

Clinical Happenings

Executive Officers of the University of Michigan Health SystemOra Hirsch Pescovitz, M.D., Executive Vice President for Medical Affairs; james O. Woolliscroft, M.D., Dean, U-M Medical School; Douglas Strong, Chief Executive Officer, U-M Hospitals and Health Centers; Kathleen Potempa, Dean, School of Nursing

The Regents of the University of Michiganjulia Donovan Darlow, Laurence B. Deitch, Denise Ilitch, Olivia P. Maynard, Andrea Fischer Newman, Andrew C. richner, S. Martin Taylor, Katherine E. White, Mary Sue Coleman (ex-officio)

Non Profit OrgUS Postage

PAIDPermit #144

Ann Arbor, MI

If you would like to schedule an appointment, transfer a patient,

or request a consult, please call

M-LINE800-962-3555

T H E M I C H I G A N D I F F E R E N C E ®

University of Michigan Health System Public Relations and Marketing Communications 2901 Hubbard, Ste. 2600 Ann Arbor, MI 48109-2435

Please let us know what you think of this publication or if you would rather receive it electronically. You can contact Physician Liaison Laurie Powell or email us at

CancerCenter@med.umich.edu

The University of Michigan, is a non-discriminatory affirmative action employer. © 2012 The regents of the University of Michigan

Lung Cancer Screening Clinic Opens

In October, the Lung Cancer Screening

clinic opened at the U-M Briarwood

Health Associates location under the

direction of Douglas Arenberg, M.D.,

an associate professor of pulmonary

diseases. The foundation for the clinic

was research conducted in part at the

University of Michigan (The National

Lung Screening Trial) which resulted

in a recommendation by the National

Comprehensive Cancer Network to make

screening of high risk patients available.

Since lung cancer screening is not a

single test, but a process, Dr. Arenberg is

available to help physicians decide if a

patient is right for the screening process.

He is also available as a resource in

dealing with abnormal incidental findings

on CT scans done for other purposes.

To reach Dr. Arenberg and his team,

call M-LINE at 800-962-3555 or e-mail

Lung-cancer-screening@umich.edu.

Liver Tumor Program Update

There has been a leadership change at

the U-M Liver Tumor Program, but the

excellent service to your patients remains

unchanged. Michael Volk, M.D., an

assistant professor of hepatology, is the

medical director, and Theodore Welling,

M.D., an assistant professor of surgery, is

the surgical director.

Drs. Volk and Welling want to ensure

that the ideal patient experience and

timely communication back to you are a

priority. They look forward to partnering

with you on your patients care.

New Clinical Trial Available A Phase 2 clinical trial lead by

Principal Investigator Ajjai Alva, MBBS

is looking at the cancer-free survival

at two years in patients with high risk

upper tract urothelial cancer when

treated with neoadjuvant cisplatin

and gemcitabine prior to surgery in

those with non-metastatic invasive

disease. For more information on

basic eligibility requirements contact

Physician Liaison Laurie Powell or visit

http://umhealth.me/SNx9fP.

University of Michigan Comprehensive Cancer Center

Max S. Wicha, M.D., Director; Marcy B. Waldinger, MHSA, Chief Administrative Officer